- Available:In stock1373
- Availability date:2020-07-30
- Dosage form:Capsules
- In stock:1373 Items
Broncho-vaccine stimulates the bodys immune defense. when using the drug with broncho-vaccine in humans, there is an increase in the level of circulating t-lymphocytes, the content of iga in saliva, a nonspecific response to polyclonal mitogens and a mixed lymphocytic reaction.
Immunotherapy. prevention of recurrent respiratory tract infections and severe infectious exacerbations of chronic bronchitis. concomitant in the treatment of acute respiratory infections.
Adults and teenagers over 12 years old
Preventive therapy / complex therapy: 1 capsule per day on an empty stomach for 10 consecutive days per month, 3 months in a row.
Treatment of exacerbations: 1 capsule per day on an empty stomach until the symptoms disappear (minimum course is 10 days). In the case of concomitant administration with antibiotics, Broncho-Vax is recommended to be used from the very beginning of treatment.
Pediatric population (children aged 6 months to 12 years): the course of therapy does not differ from the course for adults. Broncho-Vaxom Children contains a dose (3.5 mg), half that of an adult.
Note: Broncho-Vaxom capsules Children can be opened. If it is difficult for the child to swallow the capsule, its contents can be mixed in the appropriate drink (water, fruit juice, milk).
Hypersensitivity to the active substance or any auxiliary substance that is part of the broncho-vaccine.
The reported adverse events are classified below according to medra by organ system and frequency: very often (≥1 / 10), often (from ≥1 / 100 to 1/10), infrequently (from ≥1 / 1,000 to 1 / 100), rarely (from ≥1 / 10,000 to 1/1 000), very rarely (1/10 000), including isolated cases, the frequency is unknown (it is impossible to estimate from the available data).
From the immune system: infrequently - hypersensitivity reactions (erythematous rash, generalized rash, erythema, edema, edema of the eyelids, swelling of the face, peripheral edema, swelling, swelling of the face, itching, generalized itching, shortness of breath).
From the nervous system: often - headache.
From the respiratory system, chest and mediastinal organs: often - cough.
From the digestive tract: often - diarrhea, abdominal pain; infrequently - nausea, vomiting.
On the part of the skin and subcutaneous tissues: often - rash; infrequently - urticaria; frequency unknown - angioedema.
General disorders and condition of the injection site: infrequently - increased fatigue; rarely, fever.
In case of prolonged gastrointestinal or respiratory disorders, treatment should be discontinued. With skin reactions, treatment is also interrupted, since these manifestations can be of an allergic genesis.
The drug is not prescribed for broncho-vaccine in children under 6 months of age. safety and effectiveness of the drug in children under 6 months of age have not been established.
Broncho-Vaxom may cause hypersensitivity reactions. In case of development of allergic reactions or signs of intolerance to the drug, treatment should be discontinued immediately.
Influence on the ability to drive vehicles and work with other mechanisms. Broncho-Vaxom does not affect the ability to drive and use machinery.
During pregnancy and breastfeeding. There are no clinical data on the use of the drug in pregnant women. Animal experiments have not shown any direct or indirect toxicity affecting the course of pregnancy, embryo development, fetal development, and postnatal development. Regarding breastfeeding, special studies have also not been conducted and no data are available. The drug should be used with caution during pregnancy and lactation.
There is currently no data on the interaction of the drug with other drugs.
No cases of overdose have been reported at this time.the biological nature of broncho-vaccoma and the results of toxicological studies in animals indicate the impossibility of an overdose.
At a temperature of 15-25 ° C out of the reach of children.
Tags: Broncho Vaxom